How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: Unmet needs, pitfalls and advantages

Cancer Letters

Volumn 322, Issue 2, 2012, Pages 127-132

  Breccia, Massimo ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; DASATINIB; IMATINIB; INTERFERON; NILOTINIB; PEGINTERFERON ALPHA2A; PROTEIN TYROSINE KINASE INHIBITOR;

BLOOD TOXICITY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CYTOGENETICS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FOLLOW UP; HUMAN; LOW DRUG DOSE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 84861663680     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.021     Document Type: Review

References (44)

1. Faderl S., Talpaz M., Estrov Z., et al. Chronic myelogenous leukemia: biology and therapy. Ann. Intern. Med. 1999, 131:207-219.
2. Goldman J., Melo J.V. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N. Engl. J. Med. 2003, 349:1451-1464.
3. Sattler M., Griffin J.D. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin. Hematol. 2003, 40:4-10.
4. Donato N.J., Wu J.Y., Stapley J., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
5. Deininger M.W., O'Brien S.G., Guilhot F., et al. International randomized study of interferon vs STI571(IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009, 114:1126. (abstr).
6. Kantarjian H.M., O'Brien S., Cortes J., Giles F.J., Rios M.B., Shan J., Faderl S., Garcia-Manero G., Ferrajoli A., Verstovsek S., Wierda W., Keating M., Talpaz M. Imatinib mesylate therapy improbe survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 2003, 98:2636-2642.
7. Hehlmann R., Lauseker M., Jung-Munkwitz S., Leitner A., Müller M.C., Pletsch N., Proetel U., Haferlach C., Schlegelberger B., Balleisen L., Hänel M., Pfirrmann M., Krause S.W., Nerl C., Pralle H., Gratwohl A., Hossfeld D.K., Hasford J., Hochhaus A., Saussele S. Tolerability-adapted imatinib 800mg/d versus 400mg/d versus 400mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J. Clin. Oncol. 2011, 29:1634-1642.
8. de Lavallade H., Apperley J.F., Khorashad J.S., Milojkovic D., Reid A.G., Bua M., Szydlo R., Olavarria E., Kaeda J., Goldman J.M., Marin D. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J. Clin. Oncol. 2008, 26:3358-3363.
9. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., Deininger M.W., Silver R.T., Goldman J.M., Stone R.M., Cervantes F., Hochhaus A., Powell B.L., Gabrilove J.L., Rousselot P., Reiffers J., Cornelissen J.J., Hughes T., Agis H., Fischer T., Verhoef G., Shepherd J., Saglio G., Gratwohl A., Nielsen J.L., Radich J.P., Simonsson B., Taylor K., Baccarani M., So C., Letvak L., Larson R.A., IRIS investigators Five-years follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355:2408-2417.
10. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., Cervantes F., Deininger M., Gratwohl A., Guilhot F., Hochhaus A., Horowitz M., Hughes T., Kantarjian H., Larson R., Radich J., Simonsson B., Silver R.T., Goldman J., Hehlmann R., European LeukemiaNet Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 2009, 27:6041-6051.
11. Quintas-Cardama A., Kantarjian H., Jones D., Shan J., Borthakur G., Thomas D., Kornblau S., O'Brien S., Cortes J. Delayed achievement of cytogenetic and molecular response is associated with increate risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009, 113:6315-6321.
12. Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., Apperley J., Cervantes F., Cortes J., Deininger M., Gratwohl A., Guilhot F., Horowitz M., Hughes T., Kantarjian H., Larson R., Niederwieser D., Silver R., Hehlmann R., European LeukemiaNet Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108:1809-1820.
13. Marin D., Milojkovic D., Olavarria E., Khorashad J.S., de Lavallade H., Rei A.G., Foroni L., Rezvani K., Bua M., Dazzi F., Pavlu J., Klammer M., Kaeda J.S., Goldman J.M., Apperley J.F. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual out come is poor. Blood 2008, 112:4437-4444.
14. Alvarado Y., Kantarjian H., O'Brien S., Faderl S., Borthakur G., Burger J., Wierda W., Garcia-Manero G., Shan J., Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 2009, 115:3709-3718.
15. Castagnetti F., Gugliotta G., Palandri F., Breccia M., Amabile M., Iacobucci I., Testoni N., Marzocchi G., Luatti S., Specchia G., Intermesoli T., Abruzzese E., Capucci A., Levato L., Radaelli F., Martino B., Pregno P., Montefusco E., Trentin L., Alimena G., Martinelli G., Pane F., Saglio G., Baccarani M., Rosti G. Chronic myeloid leukemia (CML) patients with " suboptimal" response to imatinib (IM) according to European LeukemiaNet criteria have a poorer outcome with respect to " optimal" responders: a GIMEMA CML working party analysis. Blood 2009, 114:2196.
16. Hughes T.P., Hochhaus A., Branford S., Muller M.C., Foroni L., Druker B.J., Guilhot F., Larson R.A., O'Brien S.G., Waltzman R.J., Mone M., Wehrle E., Radich J.P., Goldman J.M. Reduction of BCR-ABL tran script levels at 6, 12 and 18 months correlates with long term outcomes on imatinib at 72months: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in patients with chronic phase chronic myeloid leukemia (CML-CP). Blood 2008, 112:334.
17. Cortes J.E., Baccarani M., Guilhot F., Druker B.J., Branford S., Kim D.W., Pane F., Pasquini R., Goldberg S.L., Kalaycio M., Moiraghi B., Rowe J.M., Tothova E., De Souza C., Rudoltz M., Yu R., Krahnke T., Kantarjian H.M., Radich J.P., Hughes T.P. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J. Clin. Oncol. 2010, 28:424-430.
18. Preudhomme C., Guilhot J., Nicolini F.E., Guerci-Bresler A., Rigal-Huguet F., Maloisel F., Coiteux V., Gardembas M., Berthou C., Vekhoff A., Rea D., Jourdan E., Allard C., Delmer A., Rousselot P., Legros L., Berger M., Corm S., Etienne G., Roche-Lestienne C., Eclache V., Mahon F.X., Guilhot F., SPIRIT Investigators France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2° in chronic myeloid leukemia. N. Engl. J. Med. 2010, 363:2511-2521.
19. Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., Pasquini R., Clark R.E., Hochhaus A., Hughes T.P., Gallagher N., Hoenekopp A., Dong M., Haque A., Larson R.A., Kantarjian H.M., ENESTnd Investigators Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 2010, 362:2251-2259.
20. H.M. Kantarjian, N.P. Shah, J.E. Cortes, M. Baccarani, M.B. Agarwal, M.S. Undurraga, J. Wang, J.J. Kassack Ipiña, D.W. Kim, M. Ogura, C. Pavlovsky, C. Junghanss, J.H. Milone, F.E. Nicolini, T. Robak, J. Van Droogenbroeck, E. Vellenga, M.B. Bradley-Garelik, C. Zhu, A, Hochhaus. Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION), Blood (2011) Dec 9 (Epub ahead of print).
21. Yeung D.T., Osborn M., White D.L., Branford S., Kornhauser M., Slader C., Issa S., Hiwase D.K., Hertzberg M.S., Schwarer A.P., Filshie R., Arthur C.K., Kwan Y.L., Forsyth C.J., Ross D., MIlls A.K., Grigg A., Hughes T.P. Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk progression-an update of the TIDEL-II trial. Blood 2011, 118:451.
22. Baccarani M., Rosti G., Castagnetti F., Haznedaroglu I., Porkka K., Abruzzese E., Alimena G., Ehrencrona H., Hjorth-Hansen H., Kairisto V., Levato L., Martinelli G., Nagler A., Lanng Nielsen J., Ozbek U., Palandri F., Palmieri F., Pane F., Rege-Cambrin G., Russo D., Specchia G., Testoni N., Weiss-Bjerrum O., Saglio G., Simonsson B. Comparison of imatinib 400mg and 800mg daily in the front-line treatment of high risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009, 113:4497-4504.
23. Palandri F., Castagnetti F., Iacobucci I., Martinelli G., Amabile M., Gugliotta G., Poerio A., Testoni N., Breccia M., Bocchia M., Crugnola M., Rege-Cambrin G., Martino B., Pierri I., Radaelli F., Specchia G., Pane F., Saglio G., Rosti G., Baccarani M. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica. 2010, 95:1415-1419.
24. Simonsson B., Gedde-Dahl T., Markevärn B., Remes K., Stentoft J., Almqvist A., Björeman M., Flogegård M., Koskenvesa P., Lindblom A., Malm C., Mustjoki S., Myhr-Eriksson K., Ohm L., Räsänen A., Sinisalo M., Själander A., Strömberg U., Bjerrum O.W., Ehrencrona H., Gruber F., Kairisto V., Olsson K., Sandin F., Nagler A., Nielsen J.L., Hjorth-Hansen H., Porkka K., Nordic CML Study Group Combination of pegylated IFN-aRb with imatinib increases molecular response rates in patients with low or intermediate-risk chronic myeloid leukemia. Blood 2011, 118:3228-3335.
25. Kantarjian H.M., Giles F.J., Bhalla K.N., Pinilla-Ibarz J., Larson R.A., Gattermann N., Ottmann O.G., Hochhaus A., Radich J.P., Saglio G., Hughes T.P., Martinelli G., Kim D.W., Shou Y., Gallagher N.J., Blakesley R., Baccarani M., Cortes J., le Coutre P.D. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow up results. Blood 2011, 117:1141-1145.
26. Shah N.P., Kim D.W., Kantarjian H., Rousselot P., Llacer P.E., Enrico A., Vela-Ojeda J., Silver R.T., Khoury H.J., Müller M.C., Lambert A., Matloub Y., Hochhaus A. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resi stance, suboptimal response or intolerance to imatinib. Haematologica. 2010, 95:232-240.
27. Gugliotta G., Castagnetti F., Breccia M., Levato L., Capucci A., Tiribelli M., Zaccaria A., Bocchia M., Cuneo A., Stagno F., Specchia G., Musso M., Martino B., Cedrone M., Intermesoli T., Palandri F., Soverini S., Baldazzi C., Durante S., Testoni N., Alimena G., Pane F., Saglio G., Baccarani M., Martinelli G., Rosti G. Early CP CML, nilotinib 400 mg twice daily frontline: beyond 3 years, results remain excellent and stable (A GIMEMA CML Working Party trial). Blood 2011, 118:2756.
28. Quintas-Cardama A., Kantarjian H., Luthra R., O'Brien S., Jabbour E., Borthakur G., Ravandi F., Garcia-Manero G., Faderl S., Konopleva M., Wierda W.G., Burton E., Cortes J.E. Efficacy of frontline nilotinib therapy in patients (Pts) with newly diagnosed Philadelphia Chromosome (Ph)-positive chronic Myeloid Leukemia in early chronic phase (CML-CP). Blood 2011, 118:454.
29. Pemmaraju N., Kantarjian H., Luthra R., O'Brien S., Jabbour E., Quintas-Cardama A., Borthakur G., Ravandi F., Verstovsek S., Burton E., Walker B., Cortes J.E. Results of a phase II trial of dasatinib as frontline therapy for chronic myeloid leukemia (CML) in chronic phase. Blood 2011, 118:1700.
30. Saglio G., le Coutre P., Pasquini R., Jootar S., Nakamae H., Flinn I.W., Hochhaus A., Hughes T.P., Larson R.A., Hoenekopp A., Gallagher N.J., Yu R., Blakesley R.E., Kim D.W., Kantarjian H.M. Nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 36-month follow-up. Blood 2011, 118:452.
31. Mahon F.X., Réa D., Guilhot J., Guilhot F., Huguet F., Nicolini F., Legros L., Charbonnier A., Guerci A., Varet B., Etienne G., Reiffers J., Rousselot P; Intergroupe Français des Leucémies Myéloïdes Chroniques Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet. Oncol. 2010, 11:1029-1035.
32. Ross D.M., Branford S., Seymour J.F., ScHwarer A.P., Arthur C., Bartley P.A., Slader C., Field C., Dang P., Filshie R.J., Mills A.K., Grigg A.P., Melo J.V., Hughes T.P. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010, 24:1719-1724.
33. Rea D., Rousselot P., Nicolini F.E., Legros L., Tulliez M., Giraudier S., Cony-Makhoul P., Guilhot F., Mahon F.X. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia (CML) patients (pts) with stable undetectable Bcr-Abl transcripts: results from the French CML group (FILMC). Blood 2011, 118:604.
34. Copland M., Hamilton A., Elrick L.J., Baird J.W., Allan E.K., Jordanides N., Barow M., Mountford J.C., Holyoake T.L. Dasatinib 8BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006, 107:4532-4539.
35. Graham S.M., Jørgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., Holyoake T.L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are in sensitive to STI571 in vitro. Blood 2002, 99:319-325.
36. Corbin A.S., Agarwal A., Loriaux M., Cortes J., Deininger M.W., Druker B.J. Human chronic myeloid leukemia stem cells are in sensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 2011, 121 396-409.
37. Jorgensen H.G., Allan E.K., Jordanides N.E., Mountford J.C., Holyoake T.L. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007, 109:4016-4019.
38. Hamilton A., Helgason G.V., Schemionek M., Zhang B., Myssina S., Allan E.K., Nicolini F.E., Muller-Tidow C., Bathia R., Brunton V.G., Koschmieder S., Holyoake T.L. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012, 119:1501-1510.
39. Chomel J.C., Bonnet M.L., Sorel N., Bertrand A., Meunier M.C., Fichelson S., Melkus M., Bennaceur-Griscelli A., Guilhot F., Turhan A.G. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011, 118:36-57-3660.
40. Carter B.Z., Mak D.H., Cortes j., Andreff M. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Semin Hematol 2010, 47:362-370.
41. Bocchia M., Gentili S., Abruzzese E., Fanelli A., Iuliano F., Tabilio A., Amabile M., Forconi F., Gozzetti A., Raspadori D., Amadori S., Lauria F. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukemia and persistent residual disease: a multicentre observational trial. Lancet 2005, 365:657-662.
42. Bellodi C., Lidonnici M.R., Hamilton A., Helgason G.V., Soliera A.R., Ronchetti M., Galavotti S., Young K.W., Selmi T., Yacobi R., Van Etten R.A., Donato N., Hunter A., Dinsdale D., Tirrò E., Vigneri P., Nicotera P., Dyer M.J., Holyoake T., Salomoni P., Calabretta B. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J. Clin. Invest. 2009, 119:1109-1123.
43. Preudhomme C., Guilhot J., Nicolini F.E., Guerci-Bresler A., Rigal-Huguet F., Maloisel F., Coiteux V., Gardembas M., Berthou C., Vekhoff A., Rea D., Jourdan E., Allard C., Delmer A., Rousselot P., Legros L., Berger M., Corm S., Etienne G., Roche-Lestienne C., Eclache V., Mahon F.X., Guilhot F., SPIRIT Investigators France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2° in chronic myeloid leukemia. N. Engl. J. Med. 2010, 363:2511-2521.
44. Zhao C., Chen A., Jamieson C.H., Fereshteh M., Abrahamsson A., Blum J., Kwon H.Y., Kim J., Chute J.P., Rizzieri D., Munchhof M., VanArsdale T., Beachy P.A., Reya T. Hedhehog signalling is essential for maintenance of cancer stem cells in myeloid leukemia. Nature 2009, 458:776-779.